AIDS HEALTHCARE FOUNDATION

Long-Acting Injectables and Novel PrEP Options Revolutionize HIV Care, Says Expert

6 months ago

• Pharmacist Jay Holloway highlights single-tablet regimens and long-acting injectables like CABENUVA as key advancements improving HIV medication adherence and patient outcomes. • The PURPOSE trial, evaluating lenacapavir for PrEP, shows promise in providing more tools to meet diverse patient needs and preferences in HIV prevention. • Holloway emphasizes the importance of addressing health disparities and supporting the overall well-being of individuals living with HIV to improve medication adherence and outcomes. • Undetectable equals untransmissible (U=U) concept is crucial; individuals with undetectable viral loads cannot transmit HIV sexually, reducing stigma and promoting public health.

Gilead's Lenacapavir: HIV Prevention Breakthrough Faces Access Challenges

8 months ago

• Gilead Sciences will roll out Lenacapavir in 120 low-income countries via royalty-free licenses, offering a twice-yearly injectable for HIV prevention. • Clinical trials showed Lenacapavir's high efficacy in reducing HIV transmission, surpassing daily oral PrEP regimens, leading to early study halts for expedited approval. • Exclusion of middle- and high-income countries with high HIV rates, like Brazil and Mexico, has drawn criticism from advocacy groups. • UNAIDS welcomes Lenacapavir's expansion but urges broader access to ensure the medication reaches all who need it to combat the global HIV epidemic.

Gilead's Lenacapavir Shows Promise in HIV Prevention and Treatment

8 months ago

• Gilead's twice-yearly injectable lenacapavir reduced HIV infections by 96% in a Phase 3 trial, demonstrating superiority to daily oral Truvada for PrEP. • The PURPOSE 2 trial included cisgender men, transgender individuals, and gender non-binary people, showing broad efficacy across diverse populations. • Gilead plans to begin regulatory filings for lenacapavir for PrEP by the end of 2024, with potential launch in 2025, prioritizing access in high-incidence, resource-limited countries. • A Phase 2 trial of once-weekly oral islatravir and lenacapavir maintained viral suppression in adults with HIV, paving the way for Phase 3 trials.